Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Ribavirin"" wg kryterium: Temat


Tytuł:
Impact of ITPA gene polymorphism for predicting anemia and treatment outcome in HCV infected patients taking Sofosbuvir Ribavirin therapy.
Autorzy:
Amjed S; University Institute of Medical Laboratory Technology, Faculty of Allied Health Sciences, The University of Lahore, Raiwind Road Campus, Lahore, Pakistan. .; Medical Laboratory Technology Department, Faculty of Rehabilitation and Allied Health Sciences, RIPHAH International University, Gulberg Campus, Lahore, Pakistan. .
Saleem HGM; University Institute of Medical Laboratory Technology, Faculty of Allied Health Sciences, The University of Lahore, Raiwind Road Campus, Lahore, Pakistan.; Medical Laboratory Technology Department, Faculty of Rehabilitation and Allied Health Sciences, RIPHAH International University, Gulberg Campus, Lahore, Pakistan.
Ullah S; University Institute of Medical Laboratory Technology, Faculty of Allied Health Sciences, The University of Lahore, Raiwind Road Campus, Lahore, Pakistan.
Latif S; Gastroenterology Department, Akthar Saeed Medical and Dental College, Lahore, Pakistan.
Shabana; Department of Microbiology and Molecular Genetics, University of the Punjab, Lahore, Pakistan.
Jafar J; Specilized Health Care and Medical Education Department, Lahore, Punjab, Pakistan.
Waqar AB; University Institute of Medical Laboratory Technology, Faculty of Allied Health Sciences, The University of Lahore, Raiwind Road Campus, Lahore, Pakistan.
Pokaż więcej
Źródło:
BMC infectious diseases [BMC Infect Dis] 2024 Mar 11; Vol. 24 (1), pp. 301. Date of Electronic Publication: 2024 Mar 11.
Typ publikacji:
Journal Article
MeSH Terms:
Hepatitis C, Chronic*/drug therapy
Hepatitis C, Chronic*/genetics
Anemia*/chemically induced
Anemia*/genetics
Hepatitis C*/drug therapy
Humans ; Ribavirin/adverse effects ; Sofosbuvir/adverse effects ; Antiviral Agents/adverse effects ; Inosine Triphosphatase ; Hepacivirus/genetics ; Prospective Studies ; Polymorphism, Single Nucleotide ; Pyrophosphatases/genetics ; Pyrophosphatases/therapeutic use ; Genotype ; Hemoglobins/genetics ; Treatment Outcome
Czasopismo naukowe
Tytuł:
The deleterious effects of sofosbuvir and ribavirin (antiviral drugs against hepatitis C virus) on different body systems in male albino rats regarding reproductive, hematological, biochemical, hepatic, and renal profiles and histopathological changes.
Autorzy:
Ali RA; Zoology Department, Faculty of Science, South Valley University, Qena, Egypt.
Awadalla EA; Zoology Department, Faculty of Science, Aswan University, Aswan, Egypt.
Amin YA; Department of Theriogenology, Faculty of Veterinary Medicine, Aswan University, Aswan, Egypt. .
Fouad SS; Qena University Hospital, South Valley University, Qena, Egypt.
Ahmed MAB; Department of Anatomy, Faculty of Medicine, South Valley University, Qena, Egypt.
Hassan MH; Department of Medical Biochemistry, Faculty of Medicine, South Valley University, Qena, Egypt.
Abdel-Kahaar E; Department of Medical Pharmacology, Faculty of Medicine, South Valley University, Qena, Egypt.; Institute of Clinical Pharmacology, Medical Faculty Mannheim, Ruprecht-Karls-University, Heidelberg, Germany.
Abdel-Aziz RH; Department of Medical Physiology, Faculty of Medicine, South Valley University, Qena, Egypt.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Mar 07; Vol. 14 (1), pp. 5682. Date of Electronic Publication: 2024 Mar 07.
Typ publikacji:
Journal Article
MeSH Terms:
Hepatitis C, Chronic*/drug therapy
Pancreatitis*/chemically induced
Humans ; Adult ; Child ; Male ; Animals ; Rats ; Antiviral Agents/adverse effects ; Sofosbuvir/adverse effects ; Ribavirin/therapeutic use ; Hepacivirus/genetics ; Acute Disease ; Treatment Outcome ; Drug Therapy, Combination ; Semen ; Sperm Motility ; Liver Cirrhosis/complications ; Lipase/genetics ; Genotype
Czasopismo naukowe
Tytuł:
Comparative efficacy and safety of Sofosbuvir/Velpatasvir and Danoprevir for the treatment of chronic hepatitis C: the real-world data in China.
Autorzy:
Zhou Y; Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, No. 600 Tianhe Road , 510630, Guangzhou City, Guangdong Province, China.
Liang M; Department of Infectious disease, The First people's hospital of Foshan, Foshan City, Guangdong Province, China.
Li Y; Department of General Practice, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou City, Guangdong Province, China.
Chen X; Department of Infectious Diseases, Yangjiang Public Health Hospital, Yangjiang City, Guangdong Province, China.
Yang J; Clinical Medicine Department of Southwest Medical University, Luzhou City, Sichuan Province, China.
Bai H; Department of Infectious disease, The First people's hospital of Foshan, Foshan City, Guangdong Province, China.
Long Y; Department of Infectious Diseases, The Eighth Hospital of Guangzhou Medical University, Guangzhou City, Guangdong Province, China.
Zhang X; Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, No. 600 Tianhe Road , 510630, Guangzhou City, Guangdong Province, China.
Lin C; Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, No. 600 Tianhe Road , 510630, Guangzhou City, Guangdong Province, China. .
Pokaż więcej
Źródło:
BMC gastroenterology [BMC Gastroenterol] 2024 Feb 14; Vol. 24 (1), pp. 73. Date of Electronic Publication: 2024 Feb 14.
Typ publikacji:
Comparative Study; Journal Article
MeSH Terms:
Benzimidazoles*
Benzopyrans*
Carbamates*
Cyclopropanes*
Drug Combinations*
Hepatitis C*/drug therapy
Hepatitis C, Chronic*/genetics
Isoindoles*
Lactams, Macrocyclic*
Proline*/analogs & derivatives
Sulfonamides*
Humans ; Antiviral Agents/adverse effects ; China ; Genotype ; Hepacivirus/genetics ; Heterocyclic Compounds, 4 or More Rings/adverse effects ; Liver Cirrhosis/drug therapy ; Retrospective Studies ; Ribavirin/adverse effects ; Sofosbuvir/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł:
In-Host HEV Quasispecies Evolution Shows the Limits of Mutagenic Antiviral Treatments.
Autorzy:
Colomer-Castell S; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Biochemistry and Molecular Biology Department, Universitat Autònoma de Barcelona (UAB), Campus de la UAB, Plaça Cívica, 08193 Bellaterra, Spain.
Gregori J; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Garcia-Cehic D; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.
Riveiro-Barciela M; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Medicine Department, Universitat Autònoma de Barcelona (UAB), Campus de la UAB, Plaça Cívica, 08193 Bellaterra, Spain.
Buti M; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Medicine Department, Universitat Autònoma de Barcelona (UAB), Campus de la UAB, Plaça Cívica, 08193 Bellaterra, Spain.
Rando-Segura A; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Microbiology Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Vico-Romero J; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Campos C; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Biochemistry and Molecular Biology Department, Universitat Autònoma de Barcelona (UAB), Campus de la UAB, Plaça Cívica, 08193 Bellaterra, Spain.
Ibañez-Lligoña M; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Medicine Department, Universitat Autònoma de Barcelona (UAB), Campus de la UAB, Plaça Cívica, 08193 Bellaterra, Spain.
Adombi CM; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Institute of Agropastoral Management, University Peleforo Gon Coulibaly, Korhogo BP 1328, Côte d'Ivoire.
Cortese MF; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Biochemistry Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Tabernero D; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Biochemistry Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Esteban JI; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Medicine Department, Universitat Autònoma de Barcelona (UAB), Campus de la UAB, Plaça Cívica, 08193 Bellaterra, Spain.
Rodriguez-Frias F; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Biochemistry Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Quer J; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Biochemistry and Molecular Biology Department, Universitat Autònoma de Barcelona (UAB), Campus de la UAB, Plaça Cívica, 08193 Bellaterra, Spain.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Dec 06; Vol. 24 (24). Date of Electronic Publication: 2023 Dec 06.
Typ publikacji:
Journal Article
MeSH Terms:
Antiviral Agents*/pharmacology
Antiviral Agents*/therapeutic use
Hepatitis E virus*/genetics
Humans ; Mutagens ; Quasispecies/genetics ; Ribavirin/pharmacology ; Ribavirin/therapeutic use
Czasopismo naukowe
Tytuł:
Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis.
Autorzy:
Flamm, Steven (AUTHOR)
Lawitz, Eric (AUTHOR)
Borg, Brian (AUTHOR)
Charlton, Michael (AUTHOR)
Landis, Charles (AUTHOR)
Reddy, K. Rajender (AUTHOR)
Shiffman, Mitchell (AUTHOR)
Alsina, Angel (AUTHOR)
Chang, Charissa (AUTHOR)
Ravendhran, Natarajan (AUTHOR)
Hernandez, Candido (AUTHOR)
Hézode, Christophe (AUTHOR)
Scherbakovsky, Stacey (AUTHOR)
Mercier, Renee-Claude (AUTHOR)
Samuel, Didier (AUTHOR)
Pokaż więcej
Źródło:
Viruses (1999-4915). Oct2023, Vol. 15 Issue 10, p2026. 14p.
Czasopismo naukowe
Tytuł:
Quasispecies Fitness Partition to Characterize the Molecular Status of a Viral Population. Negative Effect of Early Ribavirin Discontinuation in a Chronically Infected HEV Patient.
Autorzy:
Gregori J; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.
Colomer-Castell S; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Biochemistry and Molecular Biology Department, Universitat Autònoma de Barcelona (UAB), Campus de la UAB, Plaça Cívica, 08193 Cerdanyola del Vallès, Spain.
Campos C; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Biochemistry and Molecular Biology Department, Universitat Autònoma de Barcelona (UAB), Campus de la UAB, Plaça Cívica, 08193 Cerdanyola del Vallès, Spain.
Ibañez-Lligoña M; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.
Garcia-Cehic D; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.
Rando-Segura A; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Microbiology Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Adombie CM; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Institute of Agropastoral Management, University Peleforo Gon Coulibaly, Korhogo BP 1328, Côte d'Ivoire.
Pintó R; Enteric Virus Laboratory, Section of Microbiology, Virology and Biotechnology, Department of Genetics, Microbiology and Statistics, School of Biology, University of Barcelona, 08028 Barcelona, Spain.; Enteric Virus Laboratory, Institute of Nutrition and Food Safety (INSA), University of Barcelona, 08028 Barcelona, Spain.
Guix S; Enteric Virus Laboratory, Section of Microbiology, Virology and Biotechnology, Department of Genetics, Microbiology and Statistics, School of Biology, University of Barcelona, 08028 Barcelona, Spain.; Enteric Virus Laboratory, Institute of Nutrition and Food Safety (INSA), University of Barcelona, 08028 Barcelona, Spain.
Bosch A; Enteric Virus Laboratory, Section of Microbiology, Virology and Biotechnology, Department of Genetics, Microbiology and Statistics, School of Biology, University of Barcelona, 08028 Barcelona, Spain.; Enteric Virus Laboratory, Institute of Nutrition and Food Safety (INSA), University of Barcelona, 08028 Barcelona, Spain.
Domingo E; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Centro de Biología Molecular 'Severo Ochoa' (CBMSO, CSIC-UAM), Consejo Superior de Investigaciones Científicas (CSIC), Campus de Cantoblanco, 28049 Madrid, Spain.
Gallego I; Centro de Biología Molecular 'Severo Ochoa' (CBMSO, CSIC-UAM), Consejo Superior de Investigaciones Científicas (CSIC), Campus de Cantoblanco, 28049 Madrid, Spain.
Perales C; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Centro de Biología Molecular 'Severo Ochoa' (CBMSO, CSIC-UAM), Consejo Superior de Investigaciones Científicas (CSIC), Campus de Cantoblanco, 28049 Madrid, Spain.; Department of Clinical Microbiology, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM) Av. Reyes Católicos 2, 28040 Madrid, Spain.
Cortese MF; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Biochemistry Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Tabernero D; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Biochemistry Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Buti M; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Medicine Department, Universitat Autònoma de Barcelona (UAB), Campus de la UAB, Plaça Cívica, 08193 Bellaterra, Spain.
Riveiro-Barciela M; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Medicine Department, Universitat Autònoma de Barcelona (UAB), Campus de la UAB, Plaça Cívica, 08193 Bellaterra, Spain.
Esteban JI; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Medicine Department, Universitat Autònoma de Barcelona (UAB), Campus de la UAB, Plaça Cívica, 08193 Bellaterra, Spain.
Rodriguez-Frias F; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Biochemistry Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Quer J; Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, 28029 Madrid, Spain.; Biochemistry and Molecular Biology Department, Universitat Autònoma de Barcelona (UAB), Campus de la UAB, Plaça Cívica, 08193 Cerdanyola del Vallès, Spain.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2022 Nov 24; Vol. 23 (23). Date of Electronic Publication: 2022 Nov 24.
Typ publikacji:
Journal Article
MeSH Terms:
Ribavirin*/therapeutic use
Hepatitis E*/drug therapy
Hepatitis E virus*/drug effects
Hepatitis E virus*/genetics
Humans ; Follow-Up Studies ; Mutagens ; Nucleotides ; Quasispecies/genetics ; SARS-CoV-2/genetics
Czasopismo naukowe
Tytuł:
Hepatitis E case series: A UK experience.
Autorzy:
Robins A; East Suffolk and North Essex NHS Foundation Trust, Ipswich, UK.
Dolman G; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Williams S; East Suffolk and North Essex NHS Foundation Trust, Ipswich, UK.
Gelson W; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Mohsen A; East Suffolk and North Essex NHS Foundation Trust, Ipswich, UK.
Pokaż więcej
Źródło:
Journal of viral hepatitis [J Viral Hepat] 2022 Sep; Vol. 29 (9), pp. 817-822. Date of Electronic Publication: 2022 Jun 12.
Typ publikacji:
Journal Article
MeSH Terms:
Hepatitis E*/diagnosis
Hepatitis E*/drug therapy
Hepatitis E*/epidemiology
Ribavirin*/therapeutic use
Antiviral Agents/therapeutic use ; Drug Therapy, Combination ; Genotype ; Hepacivirus ; Humans ; Interferon-alpha/therapeutic use ; Polyethylene Glycols/therapeutic use ; Recombinant Proteins ; United Kingdom
Czasopismo naukowe
Tytuł:
Safety and efficacy of sofosbuvir-based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta-analysis.
Autorzy:
Elshafie S; Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Georgia, Georgia, USA.; Central Administration for Drug Control, Egyptian Drug Authority, Cairo, Egypt.
Trivedi-Kapoor R; Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Georgia, Georgia, USA.
Ebell M; Department of Epidemiology, College of Public Health, University of Georgia, Athens, Georgia, USA.
Pokaż więcej
Źródło:
Journal of clinical pharmacy and therapeutics [J Clin Pharm Ther] 2022 Aug; Vol. 47 (8), pp. 1149-1158. Date of Electronic Publication: 2022 Jun 08.
Typ publikacji:
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms:
Hepatitis C*/drug therapy
Ribavirin*/adverse effects
Sofosbuvir*/adverse effects
Antiviral Agents/adverse effects ; Drug Therapy, Combination ; Genotype ; Hepacivirus ; Hepatitis C, Chronic/drug therapy ; Humans ; Treatment Outcome
Czasopismo naukowe
Tytuł:
A randomized, placebo-controlled study to evaluate safety and pharmacokinetics of inhaled ribavirin.
Autorzy:
Couroux P; Cliantha Research, Mississauga, Ontario, Canada.
Brkovic A; Bausch Health, Laval, Quebec, Canada.
Vittitow JL; Bausch Health, Bridgewater, New Jersey, USA.
Israel RJ; Bausch Health, Bridgewater, New Jersey, USA.
Pamidi C; Cliantha Research, Mississauga, Ontario, Canada.
Patel J; Cliantha Research, Mississauga, Ontario, Canada.
Barakat M; Bausch Health, Laval, Quebec, Canada.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2022 Sep; Vol. 15 (9), pp. 2159-2171. Date of Electronic Publication: 2022 Jun 24.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Ribavirin*/adverse effects
Area Under Curve ; Cohort Studies ; Double-Blind Method ; Female ; Healthy Volunteers ; Humans ; Male
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies